Federation Des Caisses Desjardins Du Quebec Cellectis S.A. Transaction History

Federation Des Caisses Desjardins Du Quebec

$17.5 Billion
Q2 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Aug 30, 2024	SELL	$9.73 - $19.31 $2,043 - $4,055	-210 Closed	0 $0
Q4 2018 Aug 30, 2024	BUY	$15.58 - $28.41 $3,271 - $5,966	210 New	210 $3.5 Million
Q3 2018 Aug 30, 2024	BUY	$25.99 - $30.6 $5,457 - $6,426	210 New	210 $5.93 Million

Others Institutions Holding CLLS

# of Institutions

Shares Held

11.2M

Call Options Held

2.8K

Put Options Held

17.9K

Long Focus Capital Management, LLC San Juan, PR

4.62M
Shares

$8.4 Million
0.35% of portfolio
Capital International Investors Los Angeles, CA

1.85M
Shares

$3.36 Million
0.0% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$2.62 Million
0.0% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

1.44M
Shares

$2.62 Million
0.0% of portfolio
Baillie Gifford & CO

708K
Shares

$1.29 Million
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account